IP40 Stock Chart & Stats
€1.48
€0.00(0.00%)
At close: 4:00 PM EDT
€1.48
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.06 - €11.80
Previous CloseN/A
Volume0.00
Average Volume (3M)153.00
Market Cap
€5.46M
Enterprise Value€8.16M
Total Cash (Recent Filing)€6.44M
Total Debt (Recent Filing)€1.66M
Price to Earnings (P/E)―
Beta-0.45
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding4,498,772
10 Day Avg. Volume39
30 Day Avg. Volume153
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)3.90
Price to Sales (P/S)0.82
P/FCF Ratio45.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsGross margins near 90% indicate favorable economics on the products currently sold and provide substantial room to support research, commercialization, and operating investment. If maintained, this profitability at the product level can help the company improve earnings as revenue stabilizes or scales.
Moderate LeverageModerate leverage and positive shareholders’ equity provide some financial support while the company works toward profitability. Compared with a highly levered balance sheet, this structure offers greater flexibility to fund operations and develop its pharmaceutical pipeline, although leverage has been rising.
Diversified Cannabinoid PlatformInnoCan combines near-term product sales with longer-term pharmaceutical development, creating multiple potential routes to commercial value. Consumer and animal-health offerings can support market participation while proprietary delivery technologies and prescription candidates provide additional strategic upside if development succeeds.
Bears Say
Revenue ContractionDeclining revenue indicates that the current commercial base is not yet expanding and may limit the company’s ability to absorb fixed research and operating costs. Continued contraction over the next several quarters would weaken investment capacity and make progress toward sustainable profitability more difficult.
Persistent UnprofitabilityThe company remains loss-making despite strong gross margins, showing that product-level economics have not yet translated into sustainable company-wide earnings. Negative operating results can constrain internal funding for development and increase the importance of revenue growth, cost control, or external financing.
Cash BurnNegative operating and free cash flow show that the business is currently consuming cash rather than funding operations internally. The reversal from positive cash generation in 2025 raises execution risk and could create future funding needs if losses and development spending continue.
InnoCan Pharma News
IP40 FAQ
What was InnoCan Pharma’s price range in the past 12 months?
InnoCan Pharma lowest stock price was €1.06 and its highest was €11.80 in the past 12 months.
What is InnoCan Pharma’s market cap?
InnoCan Pharma’s market cap is €5.46M.
When is InnoCan Pharma’s upcoming earnings report date?
InnoCan Pharma’s upcoming earnings report date is Dec 02, 2026 which is in 32 days.
How were InnoCan Pharma’s earnings last quarter?
InnoCan Pharma released its earnings results on Aug 31, 2026. The company reported -€0.006 earnings per share for the quarter.
Is InnoCan Pharma overvalued?
According to Wall Street analysts InnoCan Pharma’s price is currently Overvalued.
Does InnoCan Pharma pay dividends?
InnoCan Pharma does not currently pay dividends.
What is InnoCan Pharma’s EPS estimate?
InnoCan Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InnoCan Pharma have?
InnoCan Pharma has 4,498,772 shares outstanding.
What happened to InnoCan Pharma’s price movement after its last earnings report?
InnoCan Pharma reported an EPS of -€0.006 in its last earnings report. Following the earnings report the stock price went up 5.396%.
Which hedge fund is a major shareholder of InnoCan Pharma?
Currently, no hedge funds are holding shares in DE:IP40
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InnoCan Pharma
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland, France, and various international markets. The company actively pursues research and development into treatments for conditions such as COVID-19, leveraging CBD delivered via exosomes and liposomes. InnoCan's product line features a range of CBD-infused topical items, including eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray. Beyond R&D, the corporation is also involved in the marketing and distribution of its proprietary CBD-enhanced pharmaceutical and cosmetic offerings. Established in 2018, InnoCan Pharma Corporation maintains its principal office in Calgary, Canada.